Upperton Pharma Solutions, a UK-based CDMO, has completed the build of its new sterile manufacturing facility in Nottingham, UK, having invested £7 million in the project.

The new facility is in addition to its existing 50,000 sq. ft facility, Trent Gateway, and the purpose-built facility has been designed specifically in line with the revised EU GMP Annex-1 regulations. The 7,000 sq. ft facility will support the manufacturing of aseptic and terminally sterilised small volume liquids and powders for parenteral, nasal and pulmonary delivery. The new facility has the capability to support formulation development, clinical manufacture and analytical testing, with batch sizes of up to 2,000 vials, pre-filled syringes and pre-filled cartridges for liquid formulations and pre-sterilized powders. This investment in sterile drug product manufacturing enhances the existing service offering from Upperton, which provides formulation development across a range of dosage forms, clinical trial supply, and late-stage manufacturing for non-sterile dosage forms for both small molecules and biologics.